ARCT - Arcturus Therapeutics Holdings Inc.
After hours:
| Previous Close | 27.07 |
| Open | 27.43 |
| Bid | 26.88 x 1000 |
| Ask | 28.10 x 1000 |
| Day's Range | 26.45 - 27.66 |
| 52 Week Range | 11.70 - 33.80 |
| Volume | |
| Avg. Volume | 520,771 |
| Market Cap | 714.013M |
| Beta (5Y Monthly) | 2.61 |
| PE Ratio (TTM) | 6.52 |
| EPS (TTM) | 4.12 |
| Earnings Date | Aug 07, 2023 - Aug 11, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 51.79 |
Business WireArcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency
SAN DIEGO, June 01, 2023--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ARCT-810, the Company’s mRNA therapeutic candidate for ornithine transcarbamylase (OTC) deficiency.
Simply Wall St.Growth Investors: Industry Analysts Just Upgraded Their Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Revenue Forecasts By 76%
Celebrations may be in order for Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ) shareholders, with the analysts...
- Investing.com
4 big analyst picks: Albemarle scores fresh Overweight rating
Here is your Pro Recap of the biggest analyst picks you may have missed since yesterday: upgrades for Albemarle, Euronav, Arcturus Therapeutics, and Palo Alto Networks. KeyBanc upgraded Albemarle (NYSE:ALB) to Overweight from Sector Weight with a price target of $270, as reported in real time on InvestingPro. KeyBanc expects demand for lithium in China to improve after a downturn that started in November 2022, noting that its recent checks from the Li industry in China indicate that inventories at the battery cell/EV OEM level are declining, and could bottom out in the coming months.
ZacksArcturus Therapeutics (ARCT) Q1 Earnings and Revenues Miss Estimates
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -69.86% and 39.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Business WireArcturus Therapeutics Announces First Quarter 2023 Financial Update and Pipeline Progress
SAN DIEGO, May 09, 2023--Arcturus Therapeutics Announces First Quarter 2023 Financial Update and Pipeline Progress
- Simply Wall St.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?
Arcturus Therapeutics Holdings' (NASDAQ:ARCT) stock is up by a considerable 29% over the past three months. But the...
Business WireArcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 9, 2023
SAN DIEGO, April 26, 2023--Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 9, 2023
- Simply Wall St.
Why Investors Shouldn't Be Surprised By Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) 79% Share Price Surge
Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ) shares have had a really impressive month, gaining 79% after a...
Motley FoolWhy Arcturus Therapeutics Stock Is Soaring Today
Shares of Arcturus Therapeutics Holdings (NASDAQ: ARCT) were soaring 25.9% higher as of 11:16 a.m. on Wednesday. The big gain came after the company provided its fourth-quarter update after the market closed on Tuesday. Fourth-quarter collaboration revenue was $160.3 million, up from $5.8 million in the prior-year period.
ZacksArcturus Therapeutics (ARCT) Beats Q4 Earnings and Revenue Estimates
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 332.80% and 19.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Business WireArcturus Therapeutics Announces Fourth Quarter 2022 Financial Update and Pipeline Progress
SAN DIEGO, March 28, 2023--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the fourth quarter ended December 31, 2022, and provided corporate updates.
- Simply Wall St.
Market Sentiment Around Loss-Making Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)
With the business potentially at an important milestone, we thought we'd take a closer look at Arcturus Therapeutics...
ZacksImmuneering Corporation (IMRX) Soars 16.9%: Is Further Upside Left in the Stock?
Immuneering Corporation (IMRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Business WireArcturus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 28, 2023
SAN DIEGO, March 07, 2023--Arcturus Therapeutics Holdings Inc. (the "Company," "Arcturus," Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter and year ended December 31, 2022 after the market close on Tuesday, March 28 and will also host a conference call and webcast
Business WireArcturus Therapeutics to Attend Upcoming Investor Conferences
SAN DIEGO, February 06, 2023--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences:
Business WireArcturus Therapeutics Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic Fibrosis
SAN DIEGO, January 31, 2023--Arcturus Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic Fibrosis
- Simply Wall St.
Swelling losses haven't held back gains for Arcturus Therapeutics Holdings (NASDAQ:ARCT) shareholders since they're up 109% over 5 years
Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ) shareholders might be concerned after seeing the share price drop...
Business WireArcturus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
SAN DIEGO, December 19, 2022--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will present at the Annual J.P. Morgan Healthcare Conference in San Francisco, on Wednesday, January 11, 2023, at 9:00 a.m. Pacific Time.
Business WireArcturus Appoints John Markels, Ph.D. to its Board of Directors
SAN DIEGO, December 13, 2022--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that is has appointed John Markels, Ph.D., an accomplished pharmaceutical executive with over 35 years of industry experience, to its Board of Directors. As part of this role, Dr. Ma
- Simply Wall St.
The Founder of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), Joseph Payne, Just Bought A Few More Shares
Whilst it may not be a huge deal, we thought it was good to see that the Arcturus Therapeutics Holdings Inc...
- Simply Wall St.
These Analysts Just Made A Significant Downgrade To Their Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) EPS Forecasts
The latest analyst coverage could presage a bad day for Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ), with the...
- Simply Wall St.
Arcturus Therapeutics Holdings Third Quarter 2022 Earnings: Beats Expectations
Arcturus Therapeutics Holdings ( NASDAQ:ARCT ) Third Quarter 2022 Results Key Financial Results Revenue: US$13.4m (up...
ZacksArcturus Therapeutics (ARCT) Reports Q3 Loss, Tops Revenue Estimates
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 33.83% and 281.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Business WireArcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline Progress
SAN DIEGO, November 09, 2022--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", "Arcturus Therapeutics", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced its financial results for the third quarter ended September 30, 2022, and provided corporate updates.
Business WireArcturus Therapeutics to Present at the Following Investor Conferences in November
SAN DIEGO, November 07, 2022--Arcturus Therapeutics Holdings Inc. (the "Company," "Arcturus," Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will present at the following investor conferences.
